February 9th 2023

FAIRplus and CARE collaboration to publish FAIR SARS-CoV-2 data

FAIRplus and CARE collaboration to publish FAIR SARS-CoV-2 data

Publishing datasets in the public domain is important to avoid the duplication of research. For effective dissemination, it is important for the datasets to be FAIR, i.e., Findable, Accessible, Interoperable and Reusable.

The IMI FAIRplus project, whose purpose was to develop tools and guidelines for making life science data FAIR, helped Janssen Pharmaceutica, one of the CARE partners, to improve the FAIRness of a dataset describing the results of ~5,500 FDA-approved drugs and clinical candidates that have passed Phase I studies, which were screened for anti-SARS-CoV-2 activity within CARE. For this purpose, they worked together on the metadata, implemented a standardized ontology and stored data on a long-term hosting platform.

You can now find the dataset on ChEMBL, a publicly accessible repository specifically for bioactive compounds.

To learn more, click here: FAIRplus use case IMI CARE: Quick-response COVID-19 effort opens FAIR data on ~5,500 compounds.